To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning. Itraconazole:Dose: 200mg once;Day5-Day7 and Day9-Day11, QD
JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning. Rifampicin:Dose: 600mg once;Day5-Day13 and Day15-Day17, QD
Cmax of JMKX003142 in plasma
Cmax of JMKX003142 when JMKX003142 administered with or without itraconazole/rifampicin
Time frame: approximately 5 days after JMKX003142 administered
AUC of JMKX003142 in plasma
AUC of JMKX003142 when JMKX003142 administered with or without itraconazole/rifampicin
Time frame: approximately 5 days after JMKX003142 administered
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.